IBDEI3AU ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,119,0)
 ;;=CHEMO NURSE PROCEDURES^2^22
 ;;^UTILITY(U,$J,358.4,120,0)
 ;;=INFUSION DRUGS^7^22
 ;;^UTILITY(U,$J,358.4,121,0)
 ;;=BLOOD PRODUCTS^1^22
 ;;^UTILITY(U,$J,358.4,122,0)
 ;;=DIAGNOSTIC PROCEDURES^3^22
 ;;^UTILITY(U,$J,358.4,123,0)
 ;;=OTHER DRUGS^8^22
 ;;^UTILITY(U,$J,358.4,124,0)
 ;;=IMMUNIZATION ADMINISTRATION^5^22
 ;;^UTILITY(U,$J,358.4,125,0)
 ;;=IMMUNIZATIONS^6^22
 ;;^UTILITY(U,$J,358.4,126,0)
 ;;=PROLONGED SVC-MD/NP/PA^9^22
 ;;^UTILITY(U,$J,358.4,127,0)
 ;;=EDUCATION/TRAINING^4^22
 ;;^UTILITY(U,$J,358.4,128,0)
 ;;=NEW PATIENT^2^23
 ;;^UTILITY(U,$J,358.4,129,0)
 ;;=ESTABLISHED PATIENT^1^23
 ;;^UTILITY(U,$J,358.4,130,0)
 ;;=CONSULTATIONS^3^23
 ;;^UTILITY(U,$J,358.4,131,0)
 ;;=COMPLEX CHRONIC CARE^4^23
 ;;^UTILITY(U,$J,358.4,132,0)
 ;;=ANEMIA^1^24
 ;;^UTILITY(U,$J,358.4,133,0)
 ;;=ARTIFICIAL OPENING STATUS^2^24
 ;;^UTILITY(U,$J,358.4,134,0)
 ;;=BREASTS and GYN NEOPLASMS^3^24
 ;;^UTILITY(U,$J,358.4,135,0)
 ;;=COAGULATION DISORDERS^4^24
 ;;^UTILITY(U,$J,358.4,136,0)
 ;;=COUNSELING AND SCREENING^5^24
 ;;^UTILITY(U,$J,358.4,137,0)
 ;;=GENITOURINARY NEOPLASMS^6^24
 ;;^UTILITY(U,$J,358.4,138,0)
 ;;=GI CANCER^7^24
 ;;^UTILITY(U,$J,358.4,139,0)
 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^24
 ;;^UTILITY(U,$J,358.4,140,0)
 ;;=HEMOGLOBINOPATHIES^9^24
 ;;^UTILITY(U,$J,358.4,141,0)
 ;;=LYMPHOID NEOPLASMS^10^24
 ;;^UTILITY(U,$J,358.4,142,0)
 ;;=METASTATIC SITES^13^24
 ;;^UTILITY(U,$J,358.4,143,0)
 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^11^24
 ;;^UTILITY(U,$J,358.4,144,0)
 ;;=MYELOID NEOPLASMS AND DISORDERS^14^24
 ;;^UTILITY(U,$J,358.4,145,0)
 ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^15^24
 ;;^UTILITY(U,$J,358.4,146,0)
 ;;=NEOPLASM OF UNSPECIFIED NATURE^16^24
 ;;^UTILITY(U,$J,358.4,147,0)
 ;;=PERSONAL HISTORY^19^24
 ;;^UTILITY(U,$J,358.4,148,0)
 ;;=MALNUTRITION^12^24
 ;;^UTILITY(U,$J,358.4,149,0)
 ;;=OTHER^18^24
 ;;^UTILITY(U,$J,358.4,150,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^20^24
 ;;^UTILITY(U,$J,358.4,151,0)
 ;;=CHEST WALL AND NECK^1^25
 ;;^UTILITY(U,$J,358.4,152,0)
 ;;=THORACIC^2^25
 ;;^UTILITY(U,$J,358.4,153,0)
 ;;=OTHER PROCEDURES^3^25
 ;;^UTILITY(U,$J,358.4,154,0)
 ;;=NEW PATIENT^2^26
 ;;^UTILITY(U,$J,358.4,155,0)
 ;;=ESTABLISHED PATIENT^1^26
 ;;^UTILITY(U,$J,358.4,156,0)
 ;;=CONSULTATIONS^3^26
 ;;^UTILITY(U,$J,358.4,157,0)
 ;;=POST-OP FOLLOW-UP^4^26
 ;;^UTILITY(U,$J,358.4,158,0)
 ;;=GENERAL SIGNS & SYMPTOMS^3^27
 ;;^UTILITY(U,$J,358.4,159,0)
 ;;=AFTERCARE POST-OP^1^27
 ;;^UTILITY(U,$J,358.4,160,0)
 ;;=POST-OP COMPLICATIONS^5^27
 ;;^UTILITY(U,$J,358.4,161,0)
 ;;=CARDIOVASCULAR^2^27
 ;;^UTILITY(U,$J,358.4,162,0)
 ;;=RESPIRATORY^7^27
 ;;^UTILITY(U,$J,358.4,163,0)
 ;;=NEOPLASM^4^27
 ;;^UTILITY(U,$J,358.4,164,0)
 ;;=PRE-OP^6^27
 ;;^UTILITY(U,$J,358.4,165,0)
 ;;=SUICIDE IDEATION/ATTEMPTS^8^27
 ;;^UTILITY(U,$J,358.4,166,0)
 ;;=ESTABLISHED PATIENT^1^28
 ;;^UTILITY(U,$J,358.4,167,0)
 ;;=CONSULTATIONS/OPINIONS^2^28
 ;;^UTILITY(U,$J,358.4,168,0)
 ;;=NEW PATIENTS^3^28
 ;;^UTILITY(U,$J,358.4,169,0)
 ;;=NEUROLOGY/SEIZURE^7^29
 ;;^UTILITY(U,$J,358.4,170,0)
 ;;=EEG^4^29
 ;;^UTILITY(U,$J,358.4,171,0)
 ;;=SLEEP TESTING^9^29
 ;;^UTILITY(U,$J,358.4,172,0)
 ;;=MUSCLE TESTING/EMG^6^29
 ;;^UTILITY(U,$J,358.4,173,0)
 ;;=EVOKED POTENTIAL^5^29
 ;;^UTILITY(U,$J,358.4,174,0)
 ;;=BIOPSY^2^29
 ;;^UTILITY(U,$J,358.4,175,0)
 ;;=AUTONOMIC FUNCTION TESTS^1^29
 ;;^UTILITY(U,$J,358.4,176,0)
 ;;=STEREOTACTIC^10^29
 ;;^UTILITY(U,$J,358.4,177,0)
 ;;=EDUCATION^3^29
